कंपनी का अवलोकन
AtaiBeckley Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the research, development, and commercialization of treatments specifically targeting mental health conditions across the United States, Germany, and Canada. The company functions within the healthcare sector and the biotechnology industry, a domain characterized by significant innovation cycles and high capital expenditure requirements for bringing novel therapies to market. As of the latest reporting period, AtaiBeckley Inc. maintains a total market capitalization of $1.34B, generates annual revenue of $4.09M, and employs approximately 99 individuals. These valuation and revenue figures indicate that the company is a mid-cap entity with a relatively small revenue base compared to its market valuation, suggesting that the stock price is heavily influenced by potential future clinical outcomes and pipeline value rather than current operational cash flows.
वित्तीय स्वास्थ्य
AtaiBeckley Inc. reported a trailing twelve-month revenue of $4.09M, accompanied by a net income loss of $-660,046,976 and an EBITDA of $-110,216,000. The substantial disparity between the modest revenue figure and the massive net income loss reveals a cost structure where expenses, likely driven by research and development activities and general administrative costs, significantly outweigh current earnings. The company recorded a free cash flow of $-54,240,752, which indicates that the organization is consuming cash reserves to fund its operations and development pipeline, thereby limiting immediate financial flexibility without additional capital raises. Margin analysis shows a gross margin of 0.0%, an operating margin of -3588.1%, and a profit margin of 0.0%, suggesting that the current business model is not generating gross profit and is operating at a severe loss relative to sales. On the liability side, the company holds $256.04M in cash against $4.57M in debt, resulting in a debt-to-equity ratio of 2.06, which presents a complex balance sheet picture of high leverage metrics alongside substantial liquidity reserves. The current ratio stands at 11.74, indicating that the company possesses more than eleven times the liquid assets required to cover its short-term obligations, a sign of strong immediate solvency despite the negative earnings. Furthermore, the return on equity is -390.0% and the return on assets is -30.8%, metrics that reflect the dilutive impact of losses on shareholder value and the utilization of assets to generate profit, respectively.
मूल्यांकन आकलन
The valuation metrics for AtaiBeckley Inc. present a distinct picture where the trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E stands at -7.62. The absence of a positive trailing P/E and the negative forward P/E imply that the market is currently pricing the stock based on future expectations of profitability that have not yet been realized or are expected to reverse the current trajectory. The price-to-book ratio is recorded at 6.06, indicating that the market values the company at six times its book value, a significant premium that suggests investors are anticipating substantial growth from the clinical pipeline or undervaluation of intangible assets. Alternative valuation measures such as the price-to-sales ratio of 328.66 and an EV/EBITDA of -9.96 further highlight that traditional profitability-based valuation models are not applicable, forcing reliance on revenue multiples and enterprise value metrics that do not account for the heavy burn rate. The stock has traded between a 52-week high of $6.75 and a 52-week low of $1.15, with the current price dynamics reflecting high volatility within this established range. The beta value of 1.57 signifies that the stock exhibits 57% higher volatility than the broader market, meaning price swings are amplified relative to general market movements.
Growth & Income
AtaiBeckley Inc. displays no year-over-year revenue growth as the metric is listed as N/A, and earnings growth is similarly unavailable due to the company's current loss status. The inability to calculate growth rates based on historical positive earnings implies that the financial trajectory is currently defined by expansion costs and clinical trial expenditures rather than scaling profits. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available resources and retained earnings are being reinvested directly into the company's growth initiatives and operational continuity. This non-dividend profile is typical for clinical-stage biotechnology firms that prioritize funding research and development over returning capital to shareholders. Overall, the growth and income profile of AtaiBeckley Inc. is characterized by a complete reliance on future value creation from its mental health treatment pipeline, with no current contribution to shareholder returns through earnings growth or dividend income.